Industry
Biotechnology
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 6:22 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 2:35 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 6:07 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Insights
June 10, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 11:00 am
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 8:13 pm
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 3:47 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 2:50 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.